Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chou2 Pharma is developing a portfolio of cannabinoid-based drugs and supplements for companion animals. The company has initiated INAD filings with the FDA Center for Veterinary Medicine and is running clinical studies on CBD/CBG for canine osteoarthritis and proprietary formulations for canine idiopathic epilepsy. Early results focus on safety, efficacy, pharmacokinetics, and pharmacodynamics. The company also markets plant-based pet supplements targeting calming, digestion, joint health, and senior comfort.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chou2 Pharma.